fig5

Figure 5. Efficacy of local SyBV administration in multiple mouse tumor models. Mice were intratumorally immunized with SyBV (10¹⁰) six times at 3-day intervals following inoculation with MC38 (colon cancer; A), EMT6 (breast cancer; B), LL/2 (Lewis lung cancer; C), or RENCA (kidney cancer; D) cells. An anti-PD-1 antibody (100 µg) was given intraperitoneally 1 day prior to immunization with SyBV. Tumor growth was monitored every 2-3 days. n = 5/group. Data are presented as mean ± SEM. ^*P < 0.05, ^***P < 0.001 by two-way ANOVA with Tukey’s post-test vs. the sham group. SyBV: Synthetic bacterial vesicle; PD-1: programmed cell death protein 1; MC38: murine colon adenocarcinoma cell line; EMT6: murine mammary carcinoma cell line; LL/2: Lewis lung carcinoma cell line; RENCA: renal adenocarcinoma cell line; SEM: standard error of the mean; ANOVA: analysis of variance.